menu
    • menu
    [{"orgOrder":0,"company":"Delcath Systems","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ IQVIA"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Roth Capital Partners"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Series E Financing","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Serine\/threonine-protein kinase RAF","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Delcath Systems","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Delcath Systems"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Delcath Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Delcath Systems","highestDevelopmentStatusID":"7","companyTruncated":"Delcath Systems \/ Delcath Systems"}]

    Find Clinical Drug Pipeline Developments & Deals by Delcath Systems

    Menu

    Delcath Systems

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Relatlimab,Melphalan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

                            Details : Opdualag (Nivolumab) is a antibody candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Melanoma.

                            Product Name : Opdualag

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 15, 2025

                            Lead Product(s) : Nivolumab,Relatlimab,Melphalan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : University of Wisconsin, Madison

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan,Tebentafusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

                            Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Uveal Melanoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 11, 2025

                            Lead Product(s) : Melphalan,Tebentafusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delcath Gains FDA IND Clearance for HEPZATO Trial in Breast Cancer Liver Mets

                            Details : Hepzato (melphalan HCl) in combination with standard of care (SOC) is being investigated for liver-dominant metastatic breast cancer (mBC).

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan,Eribulin,Vinorelbine Tartrate,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followe...

                            Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 13, 2025

                            Lead Product(s) : Melphalan,Eribulin,Vinorelbine Tartrate,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $16.3 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Delcath Gains $16.3M Funding Through Series E Warrant Exercises

                            Details : The financing aims to advance the late-stage clinical trial studies of Hepzato (melphalan), which is being evaluated for the treatment of uveal melanoma.

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 30, 2024

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $16.3 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride,Tipiracil Hydrochloride,Trifluridine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delcath Gets FDA IND Clearance for Phase 2 Trial Of HEPZATO™ in Liver Cancer

                            Details : Hepzato kit is a drug/device product which administers melphalan directly to the liver through the HDS, being investigated in combination with trifluridine-tipiracil for metastatic colorectal cancer.

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Melphalan Hydrochloride,Tipiracil Hydrochloride,Trifluridine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan,Trifluridine,Tipiracil Hydrochloride,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followe...

                            Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Melphalan,Trifluridine,Tipiracil Hydrochloride,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aelyrin Announces 32-Week Data from Phase 2b of Izokibep in Hidradenitis Suppurativa

                            Details : Hepzato kit (melphalan) is a combination drug/device product which administers melphalan directly to the liver through the HDS. It is approved for the treatment of metastatic uveal melanoma (mUM).

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

                            Details : Alkeran (melphalan), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects via filtration of the chemotherapeutic agent from the blood.

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 09, 2022

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

                            Details : The event will feature, updated Focus trial data and the role of Hepzato™ Kit (melphalan hydrochloride for injection/Hepatic Delivery System) as a potential treatment for patients with hepatic-dominant metastatic ocular melanoma.

                            Product Name : Hepzato

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 05, 2021

                            Lead Product(s) : Melphalan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.